Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
- 1 July 2005
- journal article
- review article
- Published by SAGE Publications in Vascular Medicine
- Vol. 10 (1_suppl), S35-S43
- https://doi.org/10.1177/1358836x0501000106
Abstract
The insulin resistance syndrome (IRS) is considered to be a new target of risk-reduction therapy. The IRS is a cluster of closely associated and interdependent abnormalities and clinical outcomes that occur more commonly in insulin resistant/hyperinsulinemic individuals. This syndrome predisposes individuals to type 2 diabetes, cardiovascular diseases, essential hypertension, certain forms of cancer, polycystic ovary syndrome, nonalcoholic fatty liver disease, and sleep apnea. In patients at high risk for cardiovascular diseases, endothelial dysfunction is observed in morphologically intact vessels even before the onset of clinically mani fest vascular disease. Indeed, there are several lines of evidence that indicate that endothelial function is compromised in situations where there is reduced sensitivity to endogenous insulin. It is well established that a decreased bioavailability of nitric oxide (NO) contributes to endothelial dysfunction. Furthermore, NO may modulate insulin sensitivity. Activation of NO synthase (NOS) augments blood flow to insulin- sensitive tissues (i.e. skeletal muscle, liver, adipose tissue), and its activity is impaired in insulin resistance. Inhibition of NOS reduces the microvascular delivery of nutrients and blunts insulin-stimulated glucose uptake in skeletal muscle. Furthermore, induction of hypertension by administration of the NOS inhibitor NG-monomethyl-L-arginine is also associated with insulin resistance in rats. Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial vasodilator dysfunction and increased risk of cardiovascular diseases. An intriguing relationship exists between insulin resistance and ADMA. Plasma levels of ADMA are positively correlated with insulin resistance in nondiabetic, normotensive people. New basic research insights that provide possible mechanisms underlying the development of insulin resistance in the setting of impaired NO bioavailability will be discussed.Keywords
This publication has 84 references indexed in Scilit:
- Asymmetrical DimethylarginineCirculation, 2004
- Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in HumansCirculation, 2004
- Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine DimethylaminohydrolaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulinAmerican Journal of Physiology-Endocrinology and Metabolism, 2003
- The endothelium: a new target for therapyVascular Medicine, 2000
- Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers.Diabetes Care, 2000
- Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima IndiansThe New England Journal of Medicine, 1993
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992
- Slow Glucose Removal Rate and Hyperinsulinemia Precede the Development of Type II Diabetes in the Offspring of Diabetic ParentsAnnals of Internal Medicine, 1990
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988